Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACE trial of allogeneic multivirus-specific T cells for refractory CMV, EBV, or adenovirus infection after allogeneic HSCT
2024-512321-84-00Phase 3Authorised
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Jul 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV), Epstein-Barr virus infection and adenoviral infection comparing Allogeneic multivirus-specific T cells with Placebo (2 arms). Primary endpoints: Viral clearance and Viral progression. Planned start Jul 2024; status: authorised.
02
Drugs
allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of cytomegalovirus, adenovirus and Epstein-Barr virus antigens
03
Conditions
cytomegalovirus disease (CMV)Epstein-Barr virus infectionadenoviral infection
Beyond the preview
Go deeper on 2024-512321-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512321-84-00.